HIGH LEVELS OF ERCC1 ARE ASSOCIATED WITH CISPLATIN RESISTANCE IN NEUROBLASTOMA

被引：0
|
作者：
Meret, Henry [1 ]
Wang, Zhihong [1 ]
Liu, Yimin [1 ]
机构：
[1] Childrens Hosp Michigan, Detroit, MI 48201 USA
来源：
PEDIATRIC BLOOD & CANCER | 2011年 / 57卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：784 / 784
页数：1
相关论文
共 50 条
  • [41] PHARMACOGENOMICS LINK RS11615 OF ERCC1 TO CISPLATIN-INDUCED OTOTOXICITY
    Zehnhoff-Dinnesen, A. Am
    Deuster, D.
    Malath, I.
    Eveslage, M.
    Ciarimboli, G.
    Langer, T.
    Zolk, O.
    Juergens, H.
    Lanvers-Kaminsky, C.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 164 - 164
  • [42] ERCC1 and ERCC2 polyrnorphisms and adult glioma
    Wrensch, M
    Kelsey, KT
    Liu, M
    Miike, R
    Moghadassi, M
    Sison, JD
    Aldape, K
    McMillan, A
    Wiemels, J
    Wiencke, JK
    NEURO-ONCOLOGY, 2005, 7 (04) : 495 - 507
  • [43] BRCA1 and ERCC1 mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer
    Lu Yuanming
    Zhang Lineng
    Song Baorong
    Peng Junjie
    Cai Sanjun
    BMC CANCER, 2013, 13
  • [44] ERCC1: A comparative genomic perspective
    Wilson, MD
    Ruttan, CC
    Koop, BF
    Glickman, BW
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2001, 38 (2-3) : 209 - 215
  • [45] ERCC1 measurements in clinical oncology
    Reed, Eddie
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (10): : 1054 - 1055
  • [46] ERCC1, XPD and RAI mRNA levels in lymphocytes are not associated with lung cancer risk in a prospective study of Danes
    Vogel, U
    Nexo, BA
    Tjonneland, A
    Wallin, H
    Hertel, O
    Raaschou-Nielsen, O
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 593 (1-2) : 88 - 96
  • [47] Higher Expression of ERCC1 May Be Associated with Resistance to Adjuvant Platinum-Based Chemotherapy in Gastric Cancer
    Wan, Jiayi
    Chao, Lin
    Lee, Arier C.
    Chen, Qi
    CANCER INVESTIGATION, 2017, 35 (02) : 85 - 91
  • [48] Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin
    Lee, Seung Hyeun
    Noh, Kyung Bo
    Lee, Ji Sung
    Lee, Eun Joo
    Min, Kyung Hoon
    Hur, Gyu Young
    Lee, Seung Heon
    Lee, Sung Yong
    Kim, Je Hyeong
    Lee, Sang Yeub
    Shin, Chol
    Shim, Jae Jeong
    Kim, Chul Hwan
    Kang, Kyung Ho
    In, Kwang Ho
    LUNG CANCER, 2013, 81 (01) : 102 - 108
  • [49] Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms
    Tzvetkov, Mladen V.
    Behrens, Gerrit
    O'Brien, Valerie P.
    Hohloch, Karin
    Brockmoeller, Juergen
    Benoehr, Peter
    PHARMACOGENOMICS, 2011, 12 (10) : 1417 - 1427
  • [50] ERCC1 Expression As a Predictive Marker of Cervical Cancer Treated with Cisplatin-based Chemoradiation
    Muallem, Mustafa Zelal
    Marnitz, Simone
    Richter, Rolf
    Koehler, Christhardt
    Sehouli, Jalid
    Arsenic, Ruza
    ANTICANCER RESEARCH, 2014, 34 (1A) : 401 - 406
12345